Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Analysis of Short-term (Operating) Activity Ratios 

Microsoft Excel

Short-term Activity Ratios (Summary)

Amgen Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Turnover Ratios
Inventory turnover 1.93 1.84 0.89 1.30 1.58
Receivables turnover 3.67 4.72 3.70 4.46 4.96
Payables turnover 5.09 6.74 5.32 4.08 4.72
Working capital turnover 9.85 5.40 2.25 3.82 3.37
Average No. Days
Average inventory processing period 189 199 411 281 231
Add: Average receivable collection period 99 77 99 82 74
Operating cycle 288 276 510 363 305
Less: Average payables payment period 72 54 69 90 77
Cash conversion cycle 216 222 441 273 228

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of short-term operating activity ratios reveals fluctuating performance over the five-year period. Several ratios demonstrate considerable volatility, while others exhibit more consistent, though not necessarily positive, trends. Overall, the period concludes with indications of improved efficiency in certain areas, but also continued challenges in others.

Inventory Management
Inventory turnover decreased significantly from 1.58 in 2021 to 0.89 in 2023, indicating a substantial slowdown in the rate at which inventory was sold. This trend reversed in subsequent years, rising to 1.84 in 2024 and 1.93 in 2025, suggesting improved inventory management. Correspondingly, the average inventory processing period lengthened from 231 days in 2021 to a peak of 411 days in 2023, before decreasing to 189 days in 2025. This mirrors the inventory turnover trend, indicating that inventory is taking less time to be converted into sales in the later years of the period.
Receivables Management
Receivables turnover declined from 4.96 in 2021 to 3.70 in 2023, suggesting a lengthening of the time required to collect receivables. It partially recovered to 4.72 in 2024, but decreased again to 3.67 in 2025. The average receivable collection period increased from 74 days in 2021 to 99 days in both 2023 and 2025, reinforcing the observation of slower collections. This suggests potential issues with credit policies or collection efforts.
Payables Management
Payables turnover exhibited an upward trend, increasing from 4.72 in 2021 to 6.74 in 2024, before decreasing to 5.09 in 2025. This indicates that the company paid its suppliers more frequently in 2024. The average payables payment period decreased from 77 days in 2021 to 54 days in 2024, then increased to 72 days in 2025, aligning with the payables turnover trend. This suggests a fluctuating ability to negotiate favorable payment terms with suppliers.
Overall Operating Efficiency
Working capital turnover demonstrated significant fluctuation. It increased from 3.37 in 2021 to 3.82 in 2022, then decreased sharply to 2.25 in 2023, before a substantial increase to 5.40 in 2024 and a further increase to 9.85 in 2025. This suggests a considerable improvement in the efficiency with which working capital is used to generate sales in the latter part of the period. The operating cycle lengthened from 305 days in 2021 to 510 days in 2023, then decreased to 288 days in 2025, reflecting the combined effects of changes in inventory, receivables, and payables. The cash conversion cycle followed a similar pattern, increasing to 441 days in 2023 and decreasing to 216 days in 2025.

In conclusion, the company experienced a period of operational instability, particularly between 2021 and 2023. However, the latter years of the period (2024 and 2025) show signs of improvement in inventory and working capital management, although receivables collection remains a potential area of concern.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Amgen Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of sales 12,037 12,858 8,451 6,406 6,454
Inventories 6,225 6,998 9,518 4,930 4,086
Short-term Activity Ratio
Inventory turnover1 1.93 1.84 0.89 1.30 1.58
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.68 4.04 4.98 4.87 5.58
Bristol-Myers Squibb Co. 5.18 5.46 4.02 4.33 4.74
Danaher Corp. 4.04 4.15 3.80 4.03 4.16
Eli Lilly & Co. 0.80 1.11 1.23 1.54 1.88
Gilead Sciences Inc. 3.51 3.66 3.64 3.75 4.08
Johnson & Johnson 2.13 2.21 2.37 2.49 2.87
Merck & Co. Inc. 2.46 2.49 2.54 2.95 2.29
Pfizer Inc. 1.51 1.65 2.45 3.82 3.40
Regeneron Pharmaceuticals Inc. 0.66 0.64 0.70 0.65 1.25
Thermo Fisher Scientific Inc. 4.85 5.06 5.06 4.60 3.88
Vertex Pharmaceuticals Inc. 0.98 1.27 1.71 2.35 2.56
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 2.23 2.46 2.55 3.06 3.11
Inventory Turnover, Industry
Health Care 7.55 7.56 7.36 7.85 7.90

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Inventory turnover = Cost of sales ÷ Inventories
= 12,037 ÷ 6,225 = 1.93

2 Click competitor name to see calculations.


The analysis of inventory turnover reveals fluctuating performance over the five-year period. Initially, a decline in inventory turnover is observed, followed by a subsequent recovery and slight improvement.

Inventory Turnover Trend
The inventory turnover ratio decreased from 1.58 in 2021 to 1.30 in 2022, indicating a slowing in the rate at which inventory was sold and replenished. This downward trend continued into 2023, with the ratio falling to 0.89, suggesting a significant slowdown in inventory activity. However, a substantial increase occurred in 2024, with the ratio rising to 1.84. This improvement persisted into 2025, with a further increase to 1.93, representing the highest ratio observed during the analyzed period.
Cost of Sales Relationship
Cost of sales generally increased over the period, rising from US$6,454 million in 2021 to US$12,858 million in 2024 before decreasing slightly to US$12,037 million in 2025. The initial decline in inventory turnover from 2021 to 2023 did not coincide with a substantial decrease in cost of sales, suggesting potential issues with inventory management or demand forecasting during those years. The subsequent increase in inventory turnover in 2024 and 2025 aligns with the elevated cost of sales, indicating improved efficiency in converting inventory into sales.
Inventory Levels
Inventory levels increased from US$4,086 million in 2021 to US$9,518 million in 2023. This increase likely contributed to the decline in inventory turnover during those years. A significant reduction in inventory occurred in 2024, falling to US$6,998 million, and continued to decrease to US$6,225 million in 2025. This reduction in inventory, coupled with the increasing cost of sales, likely drove the improvement in inventory turnover observed in the latter years of the period.

In summary, the company experienced a period of declining inventory efficiency, followed by a notable recovery. The changes in inventory turnover appear to be correlated with both cost of sales and inventory levels, suggesting that management actions related to inventory control and sales strategies have had a measurable impact.

AI Ask an analyst for more


Receivables Turnover

Amgen Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Product sales 35,148 32,026 26,910 24,801 24,297
Trade receivables, net 9,570 6,782 7,268 5,563 4,895
Short-term Activity Ratio
Receivables turnover1 3.67 4.72 3.70 4.46 4.96
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.86 5.16 4.87 5.16 5.63
Bristol-Myers Squibb Co. 4.87 5.19 4.93 5.48 5.65
Danaher Corp. 6.28 6.75 6.09 6.40 6.36
Eli Lilly & Co. 3.67 4.09 3.75 4.14 4.24
Gilead Sciences Inc. 5.89 6.47 5.78 5.65 6.01
Johnson & Johnson 5.48 5.98 5.73 5.88 6.14
Merck & Co. Inc. 5.52 6.24 5.81 6.27 5.28
Pfizer Inc. 5.27 5.55 5.33 9.24 7.16
Regeneron Pharmaceuticals Inc. 2.50 2.29 2.31 2.28 2.66
Thermo Fisher Scientific Inc. 5.01 5.23 5.21 5.53 4.92
Vertex Pharmaceuticals Inc. 5.85 6.85 6.31 6.19 6.66
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.79 5.26 4.96 5.76 5.54
Receivables Turnover, Industry
Health Care 7.58 7.97 7.66 8.22 8.00

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Receivables turnover = Product sales ÷ Trade receivables, net
= 35,148 ÷ 9,570 = 3.67

2 Click competitor name to see calculations.


An examination of the provided financial information reveals trends in product sales, trade receivables, and the receivables turnover ratio over a five-year period. Product sales demonstrate a consistent upward trajectory, while trade receivables and the receivables turnover ratio exhibit more fluctuation.

Product Sales
Product sales increased steadily from US$24,297 million in 2021 to US$35,148 million in 2025. This represents a cumulative growth of approximately 44.7% over the period. The largest year-over-year increase occurred between 2022 and 2023, followed by 2023 and 2024.
Trade Receivables, Net
Trade receivables experienced an initial increase from US$4,895 million in 2021 to US$7,268 million in 2023. However, a decrease was observed in 2024 to US$6,782 million, before rising again to US$9,570 million in 2025. This suggests potential variations in collection efficiency or changes in credit terms extended to customers. The most substantial increase in receivables occurred between 2024 and 2025.
Receivables Turnover
The receivables turnover ratio decreased from 4.96 in 2021 to 4.46 in 2022, indicating a lengthening of the average collection period. A more pronounced decline was noted in 2023, with the ratio falling to 3.70. The ratio saw a partial recovery in 2024, increasing to 4.72, but then decreased again in 2025 to 3.67. This fluctuating trend suggests inconsistency in the speed at which the company collects its receivables. The lower turnover in 2023 and 2025, despite increasing sales, warrants further investigation into potential issues with credit policies or collection processes. The ratio’s movement does not consistently align with the growth in product sales, suggesting that increases in sales are not necessarily translating into faster collection of receivables.

In summary, while product sales demonstrate strong growth, the receivables turnover ratio exhibits volatility. The increasing trade receivables, coupled with a declining receivables turnover in the latter years of the period, suggest a potential need to review and optimize credit and collection policies to ensure efficient working capital management.

AI Ask an analyst for more


Payables Turnover

Amgen Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of sales 12,037 12,858 8,451 6,406 6,454
Accounts payable 2,367 1,908 1,590 1,572 1,366
Short-term Activity Ratio
Payables turnover1 5.09 6.74 5.32 4.08 4.72
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. 5.07 5.74 5.54 5.94 6.05
Bristol-Myers Squibb Co. 3.90 3.88 3.28 3.33 3.37
Danaher Corp. 5.45 5.52 5.58 5.45 4.48
Eli Lilly & Co. 2.05 2.61 2.73 3.43 4.38
Gilead Sciences Inc. 8.72 7.50 11.81 6.25 9.36
Johnson & Johnson 2.52 2.66 2.76 2.66 2.70
Merck & Co. Inc. 3.72 3.72 4.11 4.08 2.96
Pfizer Inc. 3.07 3.17 3.72 5.04 5.53
Regeneron Pharmaceuticals Inc. 2.24 2.50 2.99 2.65 4.32
Thermo Fisher Scientific Inc. 7.27 8.18 8.97 7.67 6.83
Vertex Pharmaceuticals Inc. 3.58 3.71 3.46 3.55 4.64
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.72 4.08 4.25 4.28 4.23
Payables Turnover, Industry
Health Care 6.15 6.10 5.97 5.79 5.84

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Payables turnover = Cost of sales ÷ Accounts payable
= 12,037 ÷ 2,367 = 5.09

2 Click competitor name to see calculations.


The accounts payable activity demonstrates a fluctuating pattern over the five-year period. Cost of sales generally increased, while accounts payable and the resulting payables turnover exhibited more complex behavior.

Cost of Sales
Cost of sales remained relatively stable between 2021 and 2022, experiencing a decrease from US$6,454 million to US$6,406 million. A significant increase is then observed, rising to US$8,451 million in 2023, followed by a substantial jump to US$12,858 million in 2024. A slight decrease to US$12,037 million is noted in 2025, though remaining considerably higher than earlier years.
Accounts Payable
Accounts payable increased from US$1,366 million in 2021 to US$1,572 million in 2022, representing a moderate rise. This upward trend continued, albeit at a slower pace, reaching US$1,590 million in 2023. A more pronounced increase is seen in 2024, with accounts payable reaching US$1,908 million, and further increasing to US$2,367 million in 2025. The growth in accounts payable appears to lag behind the increases in cost of sales, particularly in 2024 and 2025.
Payables Turnover
The payables turnover ratio decreased from 4.72 in 2021 to 4.08 in 2022, indicating a lengthening of the time it takes to pay suppliers. The ratio then increased to 5.32 in 2023, suggesting improved efficiency in paying down accounts. A substantial increase to 6.74 is observed in 2024, the highest value in the period, indicating a significantly faster turnover of payables. The ratio decreased to 5.09 in 2025, remaining elevated but below the 2024 peak. The fluctuations in payables turnover generally correlate with the changes in cost of sales and accounts payable, with the largest increase coinciding with the largest increase in cost of sales.

Overall, the company appears to be managing its payables effectively, with the turnover ratio generally increasing alongside cost of sales. However, the increase in accounts payable in the later years suggests a potential shift in supplier relationships or payment terms, warranting further investigation.

AI Ask an analyst for more


Working Capital Turnover

Amgen Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets 29,057 29,030 30,332 22,186 19,385
Less: Current liabilities 25,489 23,099 18,392 15,687 12,184
Working capital 3,568 5,931 11,940 6,499 7,201
 
Product sales 35,148 32,026 26,910 24,801 24,297
Short-term Activity Ratio
Working capital turnover1 9.85 5.40 2.25 3.82 3.37
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Bristol-Myers Squibb Co. 7.83 7.79 4.60 8.30 3.95
Danaher Corp. 4.13 8.85 4.22 4.20 8.40
Eli Lilly & Co. 3.19 10.32 31.84 8.33
Gilead Sciences Inc. 4.43 3.99 5.61 8.42 8.54
Johnson & Johnson 62.88 15.94 11.81 5.95
Merck & Co. Inc. 4.28 6.19 9.29 5.16 7.62
Pfizer Inc. 10.58 8.64 11.09 4.83
Regeneron Pharmaceuticals Inc. 1.05 0.97 0.82 0.96 1.59
Thermo Fisher Scientific Inc. 3.30 4.87 4.05 5.46 5.87
Vertex Pharmaceuticals Inc. 1.64 1.83 0.93 0.85 1.02
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 6.50 7.86 6.68 7.25 5.87
Working Capital Turnover, Industry
Health Care 11.25 12.35 10.99 11.30 8.57

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Working capital turnover = Product sales ÷ Working capital
= 35,148 ÷ 3,568 = 9.85

2 Click competitor name to see calculations.


The working capital turnover ratio exhibited considerable fluctuation over the five-year period. Initial values indicated a moderate level of efficiency in utilizing working capital to generate sales, followed by periods of both improvement and decline.

Working Capital Trend
Working capital decreased from US$7,201 million in 2021 to US$6,499 million in 2022. A substantial increase was then observed in 2023, reaching US$11,940 million, before declining significantly to US$5,931 million in 2024 and further to US$3,568 million in 2025. This suggests evolving strategies regarding current asset and current liability management.
Product Sales Trend
Product sales demonstrated a consistent upward trend throughout the period. Sales increased from US$24,297 million in 2021 to US$24,801 million in 2022, then to US$26,910 million in 2023. Further growth was seen in 2024 with sales reaching US$32,026 million, and continued into 2025 with US$35,148 million in sales. This indicates a growing demand for the company’s products.
Working Capital Turnover Ratio Analysis
The working capital turnover ratio began at 3.37 in 2021 and increased to 3.82 in 2022, indicating improved efficiency in converting working capital into sales. However, the ratio decreased substantially to 2.25 in 2023, potentially due to the significant increase in working capital outpacing sales growth. A marked improvement occurred in 2024, with the ratio rising to 5.40, and continued strongly in 2025, reaching 9.85. This suggests a substantial increase in the efficiency of working capital utilization in the latter years of the period, potentially driven by improved inventory management or more efficient accounts receivable collection, alongside continued sales growth.

The divergence between working capital levels and the turnover ratio highlights a complex relationship. While working capital fluctuated, the increasing turnover ratio in the final years suggests a greater ability to generate sales from each dollar invested in working capital, despite the overall decrease in working capital balance.

AI Ask an analyst for more


Average Inventory Processing Period

Amgen Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Inventory turnover 1.93 1.84 0.89 1.30 1.58
Short-term Activity Ratio (no. days)
Average inventory processing period1 189 199 411 281 231
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 99 90 73 75 65
Bristol-Myers Squibb Co. 70 67 91 84 77
Danaher Corp. 90 88 96 91 88
Eli Lilly & Co. 454 329 298 237 194
Gilead Sciences Inc. 104 100 100 97 89
Johnson & Johnson 171 165 154 147 127
Merck & Co. Inc. 148 147 144 124 159
Pfizer Inc. 242 222 149 95 107
Regeneron Pharmaceuticals Inc. 556 572 519 562 292
Thermo Fisher Scientific Inc. 75 72 72 79 94
Vertex Pharmaceuticals Inc. 373 287 214 156 143
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 164 149 143 119 117
Average Inventory Processing Period, Industry
Health Care 48 48 50 46 46

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.93 = 189

2 Click competitor name to see calculations.


The average inventory processing period exhibited considerable fluctuation over the five-year period. Initial values indicated a relatively lengthy processing time, which increased substantially before decreasing again. Inventory turnover mirrored this pattern, though with a different scale.

Average Inventory Processing Period
The average inventory processing period began at 231 days in 2021. A significant increase was observed in 2022, rising to 281 days, and continued to climb to a peak of 411 days in 2023. This suggests a substantial slowdown in the rate at which inventory was sold and replenished during this timeframe. A marked improvement occurred in 2024, with the period decreasing to 199 days. This trend continued into 2025, with a further reduction to 189 days. The decline from 2023 to 2025 indicates improved inventory management efficiency or increased demand.
Inventory Turnover
Inventory turnover demonstrated an inverse relationship with the average inventory processing period. The ratio was 1.58 in 2021, decreasing to 1.30 in 2022, and reaching a low of 0.89 in 2023. This decline aligns with the extended processing period, indicating inventory was being held for longer durations. A substantial increase to 1.84 in 2024, followed by a further increase to 1.93 in 2025, suggests a faster rate of inventory sales and replacement, consistent with the decreasing processing period. The 2024 and 2025 values represent a return towards the initial 2021 level.

The combined trends suggest a period of inventory management challenges in 2022 and 2023, followed by successful corrective actions or favorable market conditions in 2024 and 2025. The increasing inventory turnover and decreasing processing period from 2023 to 2025 are positive indicators of operational efficiency.

AI Ask an analyst for more


Average Receivable Collection Period

Amgen Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Receivables turnover 3.67 4.72 3.70 4.46 4.96
Short-term Activity Ratio (no. days)
Average receivable collection period1 99 77 99 82 74
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 71 75 71 65
Bristol-Myers Squibb Co. 75 70 74 67 65
Danaher Corp. 58 54 60 57 57
Eli Lilly & Co. 99 89 97 88 86
Gilead Sciences Inc. 62 56 63 65 61
Johnson & Johnson 67 61 64 62 59
Merck & Co. Inc. 66 58 63 58 69
Pfizer Inc. 69 66 69 40 51
Regeneron Pharmaceuticals Inc. 146 160 158 160 137
Thermo Fisher Scientific Inc. 73 70 70 66 74
Vertex Pharmaceuticals Inc. 62 53 58 59 55
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 76 69 74 63 66
Average Receivable Collection Period, Industry
Health Care 48 46 48 44 46

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 3.67 = 99

2 Click competitor name to see calculations.


The average receivable collection period exhibited fluctuations over the five-year period. While the receivables turnover ratio demonstrated some variability, the collection period provides a clearer picture of changes in the efficiency of collecting receivables.

Average Receivable Collection Period
The average receivable collection period increased from 74 days in 2021 to 82 days in 2022, indicating a lengthening in the time required to collect receivables. This trend continued into 2023, with the period reaching 99 days. A subsequent decrease was observed in 2024, falling to 77 days. However, the period returned to 99 days in 2025, mirroring the 2023 value.
The increase in the collection period in 2022 and 2023 suggests a potential slowdown in the company’s ability to convert receivables into cash. This could be attributable to changes in credit policies, customer payment behavior, or collection efforts. The improvement in 2024 may indicate successful implementation of strategies to accelerate collections, but the return to a longer period in 2025 warrants further investigation.

The cyclical nature of the collection period, with increases followed by a decrease and then another increase, suggests the presence of underlying factors that influence the timing of cash receipts. Monitoring these factors and their impact on the collection period is crucial for maintaining optimal working capital management.

Receivables Turnover
The receivables turnover ratio generally moved inversely with the average collection period. It decreased from 4.96 in 2021 to 4.46 in 2022, and further to 3.70 in 2023, aligning with the lengthening collection period. An increase to 4.72 in 2024 coincided with the shorter collection period observed in that year. However, the ratio decreased again to 3.67 in 2025, consistent with the extended collection period.
The fluctuations in the receivables turnover ratio reinforce the observation that the company’s efficiency in collecting receivables varied over the period. A lower turnover ratio indicates that receivables are being collected more slowly, while a higher ratio suggests faster collection.

Overall, the analysis indicates a degree of inconsistency in the company’s receivables management. The return to longer collection periods and lower turnover in the most recent year suggests a need to reassess collection strategies and identify the root causes of these fluctuations.

AI Ask an analyst for more


Operating Cycle

Amgen Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period 189 199 411 281 231
Average receivable collection period 99 77 99 82 74
Short-term Activity Ratio
Operating cycle1 288 276 510 363 305
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 174 161 148 146 130
Bristol-Myers Squibb Co. 145 137 165 151 142
Danaher Corp. 148 142 156 148 145
Eli Lilly & Co. 553 418 395 325 280
Gilead Sciences Inc. 166 156 163 162 150
Johnson & Johnson 238 226 218 209 186
Merck & Co. Inc. 214 205 207 182 228
Pfizer Inc. 311 288 218 135 158
Regeneron Pharmaceuticals Inc. 702 732 677 722 429
Thermo Fisher Scientific Inc. 148 142 142 145 168
Vertex Pharmaceuticals Inc. 435 340 272 215 198
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 240 218 217 182 183
Operating Cycle, Industry
Health Care 96 94 98 90 92

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 189 + 99 = 288

2 Click competitor name to see calculations.


The operating cycle exhibited fluctuating behavior over the five-year period. Initial values increased significantly before decreasing and stabilizing. A detailed examination of the components reveals specific trends in inventory processing and receivable collection.

Average Inventory Processing Period
The average inventory processing period demonstrated substantial volatility. It increased from 231 days in 2021 to a peak of 411 days in 2023, indicating a lengthening of the time required to convert inventory into finished goods and make them available for sale. However, a significant decrease occurred in 2024, falling to 199 days, and continued to 189 days in 2025. This suggests improved inventory management practices or a shift in inventory composition in the latter years of the period.
Average Receivable Collection Period
The average receivable collection period showed a more moderate increase, rising from 74 days in 2021 to 99 days in 2023. This indicates a lengthening of the time taken to collect payments from customers. The period decreased to 77 days in 2024, but returned to 99 days in 2025, suggesting potential inconsistencies in credit and collection policies or customer payment behavior.
Operating Cycle
The operating cycle, representing the total time to convert investments in inventory and other resources into cash flows from sales, mirrored the trends observed in its component parts. It increased from 305 days in 2021 to a high of 510 days in 2023, driven primarily by the extended inventory processing period. A substantial reduction occurred in 2024, with the cycle decreasing to 276 days, followed by a slight increase to 288 days in 2025. The stabilization in 2024 and 2025 suggests that recent operational improvements have had a lasting, though not necessarily improving, effect on the overall cycle length.

Overall, the observed trends suggest a period of operational challenges culminating in 2023, followed by improvements in efficiency, particularly regarding inventory management, in 2024 and 2025. The receivable collection period remains a point of attention, exhibiting fluctuations that warrant further investigation.

AI Ask an analyst for more


Average Payables Payment Period

Amgen Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Payables turnover 5.09 6.74 5.32 4.08 4.72
Short-term Activity Ratio (no. days)
Average payables payment period1 72 54 69 90 77
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. 72 64 66 61 60
Bristol-Myers Squibb Co. 94 94 111 109 108
Danaher Corp. 67 66 65 67 82
Eli Lilly & Co. 178 140 134 106 83
Gilead Sciences Inc. 42 49 31 58 39
Johnson & Johnson 145 137 132 137 135
Merck & Co. Inc. 98 98 89 89 123
Pfizer Inc. 119 115 98 72 66
Regeneron Pharmaceuticals Inc. 163 146 122 138 84
Thermo Fisher Scientific Inc. 50 45 41 48 53
Vertex Pharmaceuticals Inc. 102 98 106 103 79
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 98 90 86 85 86
Average Payables Payment Period, Industry
Health Care 59 60 61 63 63

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.09 = 72

2 Click competitor name to see calculations.


The average payables payment period exhibited fluctuations over the five-year period. Initially, the period increased before decreasing and then stabilizing. This suggests evolving relationships with suppliers and potential shifts in working capital management strategies.

Payables Turnover
Payables turnover decreased from 4.72 in 2021 to 4.08 in 2022, indicating a slower rate of paying suppliers. However, it then increased significantly to 6.74 in 2024, suggesting improved efficiency in managing payables. A slight decrease to 5.09 was observed in 2025.
Average Payables Payment Period
The average payables payment period lengthened from 77 days in 2021 to 90 days in 2022, aligning with the decrease in payables turnover. A substantial reduction occurred in 2023, falling to 69 days, and further decreased to 54 days in 2024, mirroring the increase in payables turnover. The period then increased slightly to 72 days in 2025. This indicates a trend towards faster payment to suppliers, followed by a modest return towards a longer payment cycle.
Overall Trend
The period demonstrates a peak in 2022 at 90 days, followed by a consistent decline through 2024. The slight increase in 2025 suggests a potential stabilization of the payment period, though further monitoring is warranted to confirm this trend. The changes in both ratios suggest active management of supplier relationships and credit terms.

AI Ask an analyst for more


Cash Conversion Cycle

Amgen Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period 189 199 411 281 231
Average receivable collection period 99 77 99 82 74
Average payables payment period 72 54 69 90 77
Short-term Activity Ratio
Cash conversion cycle1 216 222 441 273 228
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc. 102 97 82 85 70
Bristol-Myers Squibb Co. 51 43 54 42 34
Danaher Corp. 81 76 91 81 63
Eli Lilly & Co. 375 278 261 219 197
Gilead Sciences Inc. 124 107 132 104 111
Johnson & Johnson 93 89 86 72 51
Merck & Co. Inc. 116 107 118 93 105
Pfizer Inc. 192 173 120 63 92
Regeneron Pharmaceuticals Inc. 539 586 555 584 345
Thermo Fisher Scientific Inc. 98 97 101 97 115
Vertex Pharmaceuticals Inc. 333 242 166 112 119
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences 142 128 131 97 97
Cash Conversion Cycle, Industry
Health Care 37 34 37 27 29

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 189 + 9972 = 216

2 Click competitor name to see calculations.


The short-term operating activity of the company, as measured by key ratios, exhibits fluctuating trends over the five-year period. Significant changes are observed in the average inventory processing period, receivable collection period, payables payment period, and consequently, the cash conversion cycle.

Average Inventory Processing Period
The average inventory processing period increased substantially from 231 days in 2021 to 411 days in 2023, representing a significant slowdown in inventory turnover. However, a marked improvement occurred in subsequent years, decreasing to 199 days in 2024 and further to 189 days in 2025. This suggests potential inefficiencies in inventory management around 2023, followed by successful corrective actions.
Average Receivable Collection Period
The average receivable collection period demonstrated a gradual increase from 74 days in 2021 to 99 days in 2023. While it decreased to 77 days in 2024, it returned to 99 days in 2025. This indicates a potential lengthening of the time required to collect payments from customers, with a slight improvement in 2024 that was not sustained.
Average Payables Payment Period
The average payables payment period increased from 77 days in 2021 to 90 days in 2022, then decreased significantly to 54 days in 2024. It subsequently rose to 72 days in 2025. This suggests a dynamic relationship with suppliers, potentially reflecting negotiation strategies or changes in supplier terms. The substantial decrease in 2024 may indicate a deliberate effort to accelerate payments to suppliers.
Cash Conversion Cycle
The cash conversion cycle mirrored the trends observed in the individual components. It increased from 228 days in 2021 to a peak of 441 days in 2023, driven primarily by the extended inventory processing period. A substantial decrease to 222 days in 2024 was followed by a slight increase to 216 days in 2025. The cycle’s length in 2023 suggests a considerable amount of cash tied up in operations, while the improvements in 2024 and 2025 indicate enhanced efficiency in managing working capital.

Overall, the period between 2021 and 2025 was characterized by volatility in working capital management. The significant increase in the cash conversion cycle in 2023 warrants further investigation, but the subsequent improvements suggest successful implementation of strategies to optimize the flow of cash within the business.

AI Ask an analyst for more